Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 3800 participants.
Also called NCT01305148
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 3,800 participants
- Sponsor
- Iverson Genetic Diagnostics, Inc.
- Registry
-
NCT01305148
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Suspended
Technical summary
Registry record NCT01305148. Randomized; quadruple masking; primary purpose prevention. Start 2011-08 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
- Acronym
- WARFARIN
- Condition
- Anti-coagulation Therapy
- Condition
- DVT (deep vein thrombosis)
- Condition
- Pulmonary Embolism
- Condition
- Joint Surgery Multiple
- Condition
- Atrial Fibrillation
- Condition
- Prosthetic Replacement of Mitral Valve
- Intervention (Device)
- Warfarin GenoSTAT Test
- Lead sponsor
- Iverson Genetic Diagnostics, Inc.
Record details
- Record id
cardio:ct-nct01305148- Content hash
a4d2779c5430c3b7bc5063ec30c7c02b079ade90c4b2b561ec8d1282c0bea929